Abstract:Our ability to conduct whole-organism toxicity tests to understand chemical safety has been outpaced by the synthesis of new chemicals for a wide variety of commercial applications. As a result, scientists and risk assessors are turning to mechanistically based studies to increase efficiencies in chemical risk assessment and making greater use of in vitro and in silico methods to evaluate potential environmental and human health hazards. In this context, the adverse outcome pathway (AOP) framework has gained traction in regulatory science because it offers an efficient and effective means for capturing available knowledge describing the linkage between mechanistic data and the apical toxicity end points required for regulatory assessments. A number of international activities have focused on AOP development and various applications to regulatory decision-making. These initiatives have prompted dialogue between research scientists and regulatory communities to consider how best to use the AOP framework. Although expert-facilitated discussions and AOP development have been critical in moving the science of AOPs forward, it was recognized that a survey of the broader scientific and regulatory communities would aid in identifying current limitations while guiding future initiatives for the AOP framework. To that end, a global horizon scanning exercise was conducted to solicit questions concerning the challenges or limitations that must be addressed to realize the full potential of the AOP framework in research and regulatory decision-making. The questions received fell into several broad topical areas: AOP networks, quantitative AOPs, collaboration on and communication of AOP knowledge, AOP discovery and development, chemical and cross-species extrapolation, exposure/toxicokinetics considerations, and AOP applications. Expert ranking was then used to prioritize questions for each category, where 4 broad themes emerged that could help inform and guide future AOP research and regulatory initiatives. In addition, frequently asked questions were identified and addressed by experts in the field. Answers to frequently asked questions will aid in addressing common misperceptions and will allow for clarification of AOP topics. The need for this type of clarification was highlighted with surprising frequency by our question submitters, indicating that improvements are needed in communicating the AOP framework among the scientific and regulatory communities. Overall, horizon scanning engaged the global scientific community to help identify key questions surrounding the AOP framework and guide the direction of future initiatives. Environ Toxicol Chem 2017;36:1411-1421. © 2017 SETAC.

Herpes Simplex Virus Type 1 in Saliva of Patients With Vestibular Neuronitis: A Preliminary Study

Radiation Adverse Outcome pathways (AOPs): examining priority questions from an international horizon-style exercise

Advancing the Adverse Outcome Pathway Framework-An International Horizon Scanning Approach

Adverse outcome pathways: opportunities, limitations and open questions

Harvesting the promise of AOPs: An assessment and recommendations

The adverse outcome pathway concept: a pragmatic tool in toxicology

AOP report: Development of an adverse outcome pathway for deposition of energy leading to abnormal vascular remodeling

Adverse Outcome Pathway Networks I: Development and Applications.

Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment

AOP Report: Development of an adverse outcome pathway for deposition of energy leading to bone loss

AOP Report: An Upstream Network for Reduced Androgen Signaling Leading to Altered Gene Expression of Androgen Receptor–Responsive Genes in Target Tissues

The First Steps on AOPs' Concepts, Development, and Applications in Teratology

Adverse Outcome Pathway Networks II: Network Analytics.

Potential adverse outcome pathways with hazard identification of organophosphate esters

Proof of concept for quantitative adverse outcome pathway modeling of chronic toxicity in repeated exposure

A toxicity pathway-oriented approach to develop adverse outcome pathway: AHR activation as a case study

Hidradenitis Suppurativa (HS), in Association with Helicobacter Pylori, in a Female Sudanese Patient: Case Report

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

Development of an adverse outcome pathway network for nephrotoxicity

The skin sensitization adverse outcome pathway: exploring the role of mechanistic understanding for higher tier risk assessment

Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework